Stem Cells (STEM) has announced the first patient to receive a high dose of one million purified human neural stem cells (HuCNS-SC®) in their Phase 1/2 clinical trial. This followed an independent review by the Data Safety Monitoring Committee, which found no safety issues with proceeding to the high dose. The 16-patient trial is designed to evaluate the [Read More]
Category: Latest News
Prevent Blindness America Launches New Online Resource, "Living Well with Low Vision"
To directly address the needs of those with low vision and their caregivers, Prevent Blindness America has launched a new online resource: “Living Well with Low Vision”. The goal of the new website is to make it as easy as possible for people to educate themselves about loss of vision, to meet the daily challenges [Read More]
New Stem Cell Eye Treatment Study Beginning
(Updated March 12, 2017) MD Stem Cells has announced a new and extensive stem cell study to determine effectiveness of stem cells in ophthalmic disease. The company has been named collaborator for the new Stem Cell Ophthalmology Treatment Study (SCOTS), being conducted in Florida. Conditions eligible for the new study include retinal diseases such as age-related [Read More]
Eylea Approved in Europe for CRVO
Regeneron Pharmaceuticals’ Eylea (aflibercept) treatment for central retinal vein occlusion (CRVO) has been approved by the European Commission. Eylea was approved in the United States for the treatment of neovascular (wet) age-related macular degeneration (AMD) in 2011, and for macular edema following CRVO in 2012. The drug has also been approved in Europe, Japan, Australia, [Read More]
Statin Therapy Lowers Risk of Cataracts
by Dan Roberts Statin therapy has been shown to reduce inflammation in the retina, but there has been some concern about cataract development for those who use the drugs. In a press conference at the European Society of Cardiology meeting, Aug 30, 2013, John B. Kostis, MD (UMDNJ-Robert Wood Johnson Medical School, New Brunswick, N.J.) [Read More]